We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
Cap. Flow
+$40.7M
Cap. Flow %
1.55%
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$47.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$18.8M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.7M
5
PFE icon
Pfizer
PFE
+$13.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.2M
2
SYK icon
Stryker
SYK
+$24.6M
3
ZBH icon
Zimmer Biomet
ZBH
+$24M
4
HUM icon
Humana
HUM
+$20.2M
5
UNH icon
UnitedHealth
UNH
+$17.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.54%
2 Real Estate 2.01%
3 Industrials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLCM
176
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.98K ﹤0.01%
6,000
– –
ACAD icon
177
Acadia Pharmaceuticals
ACAD
$4.39B
– –
-72,225
Closed -$1.15M
ARVN icon
178
Arvinas
ARVN
$520M
– –
-42,998
Closed -$1.47M
HQY icon
179
HealthEquity
HQY
$8.72B
– –
-110,214
Closed -$6.79M
IDYA icon
180
IDEAYA Biosciences
IDYA
$3.41B
– –
-133,185
Closed -$2.42M
MLTX icon
181
MoonLake Immunotherapeutics
MLTX
$1.48B
– –
-300,000
Closed -$3.15M
PLRX icon
182
Pliant Therapeutics
PLRX
$64.4M
– –
-35,233
Closed -$681K
PTGX icon
183
Protagonist Therapeutics
PTGX
$8.51B
– –
-122,271
Closed -$1.33M
STVN icon
184
Stevanato
STVN
$5.62B
– –
-71,190
Closed -$1.28M
XNCR icon
185
Xencor
XNCR
$1.44B
– –
-200,328
Closed -$5.22M
MORF
186
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-44,625
Closed -$1.19M
ALR
187
DELISTED
AlerisLife Inc
ALR
– –
-24,237
Closed -$13.3K
ONEM
188
DELISTED
1Life Healthcare
ONEM
– –
-31,266
Closed -$522K
HZNP
189
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-415,053
Closed -$47.2M
4 5 6 7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
  • Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
  • Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
  • Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
  • Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
  • Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.